Merck & Company Inc (MRK)vsProtagonist Therapeutics Inc (PTGX)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
PTGX
Protagonist Therapeutics Inc
$148.18
+2.08%
HEALTHCARE · Cap: $9.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23507% more annual revenue ($66.57B vs $281.99M). PTGX leads profitability with a 29.4% profit margin vs 4.8%. MRK trades at a lower P/E of 116.1x. PTGX earns a higher WallStSmart Score of 63/100 (C+).
MRK
Hold36
out of 100
Grade: F
PTGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for PTGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Strong operational efficiency at 74.4%
Revenue surging 3749.0% year-over-year
Earnings expanding 351.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Trading at 11.4x book value
Weak financial health signals
Premium valuation, high expectations priced in
ROE of -17.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PTGX
The strongest argument for PTGX centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 74.4%. Revenue growth of 3749.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Piotroski F-Score, P/E Ratio. A P/E of 140.9x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while PTGX is a growth play — different risk/reward profiles.
PTGX carries more volatility with a beta of 1.79 — expect wider price swings.
PTGX is growing revenue faster at 3749.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PTGX scores higher overall (63/100 vs 36/100), backed by strong 29.4% margins and 3749.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?